2022
Depression, Anxiety, and Patterns of Mental Health Care Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy
Tsao P, Ross R, Bohnert A, Mukherjee B, Caram M. Depression, Anxiety, and Patterns of Mental Health Care Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy. The Oncologist 2022, 27: 314-322. PMID: 35298660, PMCID: PMC8982372, DOI: 10.1093/oncolo/oyab033.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyMental health careProstate cancerMental health treatmentDiagnosis of depressionHealth careOptum's de-identified Clinformatics Data Mart DatabaseProstate cancer treated with androgen deprivation therapyInitiation of androgen deprivation therapyHealth treatmentPatterns of mental health careClinformatics Data Mart DatabaseSerotonin reuptake inhibitorsAnxiety diagnosesPsychotropic medicationsSpecialty of providersData Mart DatabasePrimary care physiciansPrescribing of psychotropic medicationsIncidence of depressionProportion of menDeprivation therapyReuptake inhibitorsMedian timeProstate
2020
Depression, anxiety, and patterns of mental health care among men with prostate cancer on androgen deprivation therapy (ADT).
Tsao P, Ross R, Bohnert A, Mukherjee B, Caram M. Depression, anxiety, and patterns of mental health care among men with prostate cancer on androgen deprivation therapy (ADT). Journal Of Clinical Oncology 2020, 38: 12100-12100. DOI: 10.1200/jco.2020.38.15_suppl.12100.Peer-Reviewed Original ResearchDiagnosis of depressionMental health carePatterns of mental health careAndrogen deprivation therapyReuptake inhibitorsHealth careProstate cancerSerotonin-norepinephrine reuptake inhibitorsReceipt of psychotherapySerotonin reuptake inhibitorsNorepinephrine reuptake inhibitorsDevelopment of depressionIncreased risk of depressionRisk of depressionRisk of dependenceDatabase of commercially insured patientsCare of menPsychiatric medicationsPsychotherapyAnxietyCognitive impairmentDepressionCommercially insured patientsIncident useAnalytic cohort
2019
Patient and Provider Variables Associated with Variation in the Systemic Treatment of Advanced Prostate Cancer.
Caram M, Wang S, Tsao P, Griggs J, Miller D, Hollenbeck B, Lin P, Mukherjee B. Patient and Provider Variables Associated with Variation in the Systemic Treatment of Advanced Prostate Cancer. Urology Practice 2019, 6: 234-242. PMID: 31276025, PMCID: PMC6605774, DOI: 10.1097/upj.0000000000000020.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerAndrogen signaling inhibitorsAdvanced prostate cancerFirst-line treatmentProstate cancerSystemic treatment of advanced prostate cancerDatabase of commercially insured patientsTreatment of advanced prostate cancerCastration-resistant prostate cancerSignaling inhibitorsPre-existing heart failureImproved overall survivalTreatment of menCommercially insured patientsSipuleucel-TRadium-223Overall survivalSystemic treatmentTreatment patternsNovel therapiesMedical oncologistsHeart failureMultivariate analysisProvider specialtyDocetaxelFactors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer
Caram M, Ross R, Lin P, Mukherjee B. Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer. JAMA Network Open 2019, 2: e192589. PMID: 31002323, PMCID: PMC6481456, DOI: 10.1001/jamanetworkopen.2019.2589.Peer-Reviewed Original ResearchConceptsMinimally symptomatic metastatic castration-resistant prostate cancerSipuleucel-TProstate cancerSymptomatic metastatic castration-resistant prostate cancerDatabase of commercially insured patientsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerAge of patientsRetrospective cohort studyFactors associated with useAssociated with patientsCommercially insured patientsPatterns of treatmentConcurrent therapyTreated patientsCohort studyMultivariate analysisCancer therapyTherapyPatientsPhysician factorsCancerBarriers to treatmentBinomial logistic regressionLogistic regression
2018
Patient and provider variables associated with variation in the systemic treatment of advanced prostate cancer.
Caram M, Wang S, Cheng P, Griggs J, Lin P, Mukherjee B. Patient and provider variables associated with variation in the systemic treatment of advanced prostate cancer. Journal Of Clinical Oncology 2018, 36: e17019-e17019. DOI: 10.1200/jco.2018.36.15_suppl.e17019.Peer-Reviewed Original ResearchTemporal and geographic variation in the systemic treatment of advanced prostate cancer
Caram M, Estes J, Griggs J, Lin P, Mukherjee B. Temporal and geographic variation in the systemic treatment of advanced prostate cancer. BMC Cancer 2018, 18: 258. PMID: 29510667, PMCID: PMC5840834, DOI: 10.1186/s12885-018-4166-3.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerFirst-line therapyProstate cancerSystemic treatmentFirst-lineSystemic treatment of advanced prostate cancerTreatment of metastatic castration-resistant prostate cancerTreatment of advanced prostate cancerResultsOur final analysisAdvanced prostate cancerFirst line therapyFood and Drug AdministrationNational insurance providerLine therapySequence of treatmentTreatment patternsDisease courseStudy cohortPrescription ratesPrescribed drugsDrug AdministrationIncreased survivalCancerTherapy
2017
Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D
Caram M, Borza T, Min H, Griggs J, Miller D, Hollenbeck B, Mukherjee B, Skolarus T. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. JCO Oncology Practice 2017, 13: jop.2016.020206. PMID: 28628393, PMCID: PMC5555032, DOI: 10.1200/jop.2016.020206.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerHospital referral regionsProstate cancerMetastatic castration-resistant prostate cancer treatmentCastration-resistant prostate cancerProvider specialtyAdvanced prostate cancerMedicare Part DProstate cancer incidenceFood and Drug AdministrationMinority of providersYears of ageEnzalutamide prescriptionsMultilevel regression modelsMedicare Part D dataPart DEnzalutamideAbirateroneMedical oncologistsMedical oncologyEarly disseminationTreated menPart D dataCancer incidenceWorkforce densityEarly national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D.
Caram M, Borza T, Min H, Griggs J, Miller D, Hollenbeck B, Mukherjee B, Skolarus T. Early national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D. Journal Of Clinical Oncology 2017, 35: 35-35. DOI: 10.1200/jco.2017.35.8_suppl.35.Peer-Reviewed Original ResearchAdvanced prostate cancerHospital referral regionsProstate cancerProvider specialtyAdvanced prostate cancer treatmentProstate cancer incidenceProstate cancer treatmentMedicare Part DEnzalutamide prescriptionsFood & Drug AdministrationMedicare Part D dataEnzalutamideMinority of providersAbirateroneMedical oncologistsOral medicationsMedical oncologyEarly disseminationTreated menPart D dataCancer incidenceDrug AdministrationCancer treatmentMultilevel regression modelsPart D
2013
Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome
Raymond V, Mukherjee B, Wang F, Huang S, Stoffel E, Kastrinos F, Syngal S, Cooney K, Gruber S. Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome. Journal Of Clinical Oncology 2013, 31: 1713-1718. PMID: 23530095, PMCID: PMC3641694, DOI: 10.1200/jco.2012.44.1238.Peer-Reviewed Original ResearchConceptsLynch syndromeCumulative lifetime riskRisk of prostate cancerAge-specific cumulative riskLifetime risk of prostate cancerFamilial cancer registryGeneral populationHazard ratioCumulative risk of prostate cancerModified segregation analysisProstate cancerFourth-degree relativesCumulative riskProstate cancer riskLS familiesCancer RegistryCancer riskLifetime riskCases of prostate cancerPopulation riskMismatch repair-deficient phenotypeWald-type CICancer diagnosisMutation carriersElevated risk
1996
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
Pinto J, Suffoletto B, Berzin T, Qiao C, Lin S, Tong W, May F, Mukherjee B, Heston W. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clinical Cancer Research 1996, 2: 1445-51. PMID: 9816319.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, SurfaceCarboxypeptidasesCell FractionationCell MembraneFolic AcidGamma-Glutamyl HydrolaseGlutamate Carboxypeptidase IIHumansHydrogen-Ion ConcentrationHydrolasesImmunohistochemistryMaleMethotrexatePolyglutamic AcidProstatic NeoplasmsPteroylpolyglutamic AcidsSubstrate SpecificityTumor Cells, CulturedConceptsFolate hydrolase activityProtein prostate-specific membrane antigenHuman prostate cancerPC-3 cellsProstate cancerMembrane-bound enzymeHydrolase activityMonoclonal antibodiesLNCaP cellsTransfection of PC-3 cellsResistance to methotrexate therapyClass II membrane proteinHuman prostate cancer cell linesTreatment of prostate cancerMembrane fractionProstate cancer cell linesHuman prostate carcinoma cellsLNCaP cell membranesProstate-specific membraneHuman prostate adenocarcinoma cellsPhase 3 trialProstate carcinoma cellsProstate adenocarcinoma cellsAbsence of thiol reagentsEukaryotic expression vector